PubRank

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer (MONARCH 2)

Clinical Trial ID NCT02107703

PubWeight™ 12.03‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02107703

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov 2015 1.27
2 Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res 2016 0.87
3 Breast Cancer Update 2014 - Focus on the Patient and the Tumour. Geburtshilfe Frauenheilkd 2015 0.85
4 Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Cancer Manag Res 2016 0.85
5 The Role of CDK4/6 Inhibition in Breast Cancer. Oncologist 2015 0.83
6 Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors. Int J Cancer Clin Res 2015 0.81
7 Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. J Hematol Oncol 2015 0.80
8 Does CDKN2A loss predict palbociclib benefit? Curr Oncol 2015 0.80
9 Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer. Onco Targets Ther 2015 0.78
10 Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. Breast Care (Basel) 2016 0.77
11 Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl) 2016 0.76
12 The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2019 0.75
13 Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer. Viszeralmedizin 2015 0.75
14 New directions for drug-resistant breast cancer: the CDK4/6 inhibitors. Future Med Chem 2015 0.75
15 First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer. P T 2015 0.75
16 Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer. Onco Targets Ther 2016 0.75
Next 100